---
title: "Adipotide"
canonical_url: https://peptidelibrary.app/library/adipotide
description: "Experimental chimeric peptide designed to induce apoptosis in white-adipose vasculature via prohibitin targeting. Not FDA-approved; development did not yield a drug."
updated: 2026-11-07
publisher: Peptide Library
notice: "Research and educational use only. Not medical advice."
---

# Adipotide

Adipotide (also called FTPP or Prohibitin-targeting peptide) is an experimental fat-vasculature targeting peptide in the Targeted peptidomimetic class. Adipotide is a peptidomimetic built from two functional parts joined together. The first is the homing sequence CKGGRAKDC, selected by phage display for binding prohibitin, a protein reported to be selectively displayed on the surface of endothelial cells in white adipose tissue vasculature.

Experimental chimeric peptide designed to induce apoptosis in white-adipose vasculature via prohibitin targeting. Not FDA-approved; development did not yield a drug.

Also known as: FTPP, Prohibitin-targeting peptide.

Categories: Fat Loss, GLP-1/Metabolic, Experimental.

## Classification

- Type: Experimental fat-vasculature targeting peptide
- Mechanism class: Targeted peptidomimetic
- Development stage: Research only
- Regulatory class: Research compound, not FDA-approved

## Mechanism

Adipotide is a peptidomimetic built from two functional parts joined together. The first is the homing sequence CKGGRAKDC, selected by phage display for binding prohibitin, a protein reported to be selectively displayed on the surface of endothelial cells in white adipose tissue vasculature. The second is a KLAKLAK dimer, a pro-apoptotic domain that is inactive outside cells but disrupts mitochondrial membranes once internalised. The design intent is targeted ablation of the blood supply to fat tissue rather than any action on adipocyte metabolism, causing adipose tissue to regress through loss of perfusion. In primate studies this produced weight reduction, but renal toxicity was observed, and development did not proceed.

Targets: Prohibitin (adipose vasculature).

Origin: Synthetic targeted peptidomimetic.

## Properties

- Molecular formula: C111H206N36O28S2
- Molecular weight: 2,557.2 g/mol
- CAS number: 859216-15-2

## Evidence

- Evidence level: Insufficient Evidence
- Highest documented: Early or uncontrolled human studies
- Human trials: 1
- Controlled human trials: 0
- Preclinical sources: 1
- Latest source: 2011

No human dose is established for this compound.

Each step shows whether the sources Peptide Library has reviewed include that kind of research. Counts are reviewed sources, not every study ever published. Reviews and programme summaries that describe human use are shown as "reported", not as trials, and registered trials without published results are listed but not counted. A higher step means research has progressed further; it does not mean a compound works better or is safer. Compounds whose evidence has not been reviewed yet show "Not reviewed" instead of a guess.

### Studies

1. NCT01262664 — A First-in-Man, Phase I Evaluation of A Single Cycle of Prohibitin Targeting Peptide 1 in Patients With Metastatic Prostate Cancer and Obesity. Human study (early or uncontrolled). Population: Men with metastatic prostate cancer and obesity (n=4 enrolled). Safety and tolerability (no results posted) [Source](https://clinicaltrials.gov/study/NCT01262664)
2. A peptidomimetic targeting white fat causes weight loss and improved insulin resistance in obese monkeys. Sci Transl Med. 2011. 2011. Preclinical: animal or lab study. Population: Obese monkeys from three species. Weight loss and improved insulin resistance, with reversible changes in kidney tubule function. Limitations: Lab or animal research: not evidence of a human effect or dose. [Source](https://pubmed.ncbi.nlm.nih.gov/22072637/)

### Registered trials

- [NCT01262664](https://clinicaltrials.gov/study/NCT01262664)

## Safety

Side effects: Renal toxicity signal in animals; No human dose.

Risks: WADA S0; Do not treat as a fat-loss drug.

Human safety basis: No controlled human safety data

Key limitations: No established human dosage.; No controlled human trial results in the reviewed sources.; Not approved by the FDA for any use..

## Regulatory status

Adipotide is not an FDA-approved product. It is sold for laboratory research and has no approved medical use.

- FDA status: Not Approved
- WADA status: Banned in Sport
- Availability: Research-Only

## Frequently asked questions

### What is Adipotide?

Experimental chimeric peptide designed to induce apoptosis in white-adipose vasculature via prohibitin targeting. Not FDA-approved; development did not yield a drug.

### How does Adipotide work?

Adipotide is a peptidomimetic built from two functional parts joined together. The first is the homing sequence CKGGRAKDC, selected by phage display for binding prohibitin, a protein reported to be selectively displayed on the surface of endothelial cells in white adipose tissue vasculature.

### Is Adipotide FDA approved?

No. Adipotide is not approved by the FDA for any indication and is categorised as research-only. It has not been reviewed for safety or efficacy as a medicine, and published research should be read as investigation rather than established use.

### Is Adipotide banned in sport?

Adipotide is recorded here as prohibited in sport. Athletes subject to anti-doping rules should check the current WADA Prohibited List directly, since it is revised annually and classifications change.

### What peptides are similar to Adipotide?

Compounds most often compared with Adipotide include 5-Amino-1MQ, AICAR, Angiotensin (1-7) Analog and AOD-9604. They are grouped by shared mechanism or research area rather than by equivalence, and their regulatory status and evidence base differ.

## References

- [WADA Prohibited List 2026](https://www.wada-ama.org/en/prohibited-list)
- [Prohibitin: targeting peptide coupled to ovarian cancer, luteinization and TGF-β pathways — J Ovarian Res, 2017](https://pubmed.ncbi.nlm.nih.gov/28427435/)
- [Fatty Liver/Adipose Tissue Dual-Targeting Nanoparticles with Heme Oxygenase-1 Inducer for Amelioration of Obesity, Obesity-Induced Type 2 Diabetes, and Steatohepatitis — Adv Sci (Weinh), 2022](https://pubmed.ncbi.nlm.nih.gov/36209391/)
- [A comparative study between nanoparticle-targeted therapeutics and bioconjugates as obesity medication — J Control Release, 2013](https://pubmed.ncbi.nlm.nih.gov/23871959/)
- [Comment on "a peptidomimetic targeting white fat causes weight loss and improved insulin resistance in obese monkeys" — Sci Transl Med, 2012](https://pubmed.ncbi.nlm.nih.gov/22539771/)
- [A peptidomimetic targeting white fat causes weight loss and improved insulin resistance in obese monkeys — Sci Transl Med, 2011](https://pubmed.ncbi.nlm.nih.gov/22072637/)
